Online pharma sale can't be regulated till Centre makes rules: TN regulator

The counter affidavit was filed by the Director of Drugs Control in a petition filed by the TNCDA seeking an order against online sales of medicines through e-pharmacy websites

The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth
The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth
Gireesh Babu Chennai
Last Updated : Nov 20 2018 | 12:58 AM IST
In the latest development in the litigation against online pharmacy sales in the country, the State Food Safety and Drug Administration Department of Tamil Nadu has submitted before the court that the online sale of medicines cannot be regulated until rules governing it are framed.   

The counter affidavit was filed by the Director of Drugs Control in a petition filed by the Tamil Nadu Chemists and Druggists Association (TNCDA) seeking an order against online sales of medicines through e-pharmacy websites, since it is not permitted under the prevailing Drugs and Cosmetics Act and the granting of permission for such activities is in progress through a draft rule.   

The state administration submitted that blocking the links of the online pharmacies was not under the purview of the provisions of the Drugs and Cosmetics Act. It added that the state government did not have any role in any addition or deletion in and amendment to the concerned Act and Rules.  

"Therefore, unless and until there are any rules governing the same, online sale cannot be regulated. What cannot be regulated cannot be permitted. The Act recognises and permits only certain manner of sale/vending particularly retail," said the counter, adding that the writ petition was not maintainable at present and was liable to be dismissed.

On October 31, the court issued an interim order restricting online sale of medicines without a license and directed the Government of India or competent authority to stall such online sales. 

Six online pharmacy firms -- 1MG Technologies, Digital Health Platforms, Netmeds Market Place, 91 Streets Media Technologies, Medline International and Practo Technologies -- have been impleded in the matter and sought the court to clarify that the ban was only on unauthorised sellers. They argued that they sell only based on prescriptions and through registered pharmacists. The online aggregators said that they can give an undertaking that they are selling only from licensed pharmacies. Companies such as Netmeds argued that they already have a license to sell medicines and they should not be affected because of the order. 

On Monday, the Chennai-based online pharmacy TNMEDS and a regional pharmacists' organisation were also impleded in the matter. The court adjourned the hearing to December 5, with the central government yet to file its counter affidavit on the matter.  


TNCDA has been arguing that the prevailing regulation has no provisions for selling medicines through the online channel and draft rules for the same are still under consideration, which shows that the current online sales of medicines are not legal.  

From a market size of $12.6 billion in 2009, the Indian pharmaceutical market is expected to grow to $55 billion by 2020, with the potential to reach $70 billion in an aggressive growth scenario. 

ResearchAndMarkets.com estimates that e-pharmacy's market potential is worth over a billion dollars, with global and domestic industry giants such as Amazon and Flipkart, along with more than 30 start-ups, trying to grab the pie.  

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story